APG Asset Management N.V. Raises Stock Position in Stryker Co. (NYSE:SYK)

APG Asset Management N.V. raised its holdings in Stryker Co. (NYSE:SYK - Free Report) by 1,695.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 370,226 shares of the medical technology company's stock after purchasing an additional 349,601 shares during the quarter. APG Asset Management N.V. owned 0.10% of Stryker worth $128,730,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SYK. Kohmann Bosshard Financial Services LLC purchased a new position in Stryker during the fourth quarter valued at approximately $25,000. Dunhill Financial LLC grew its stake in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock worth $27,000 after purchasing an additional 37 shares during the period. Rakuten Securities Inc. increased its holdings in shares of Stryker by 618.2% during the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after purchasing an additional 68 shares in the last quarter. Centricity Wealth Management LLC purchased a new stake in Stryker during the fourth quarter worth $30,000. Finally, BankPlus Trust Department acquired a new stake in Stryker during the fourth quarter valued at $33,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Trading Up 0.5 %

NYSE:SYK traded up $1.63 during trading hours on Friday, hitting $350.02. The company had a trading volume of 1,767,159 shares, compared to its average volume of 1,358,209. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average of $375.54 and a 200 day moving average of $373.55. The company has a market cap of $133.60 billion, a P/E ratio of 45.11, a P/E/G ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the company earned $3.46 earnings per share. Sell-side analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.96%. Stryker's payout ratio is 43.30%.

Wall Street Analysts Forecast Growth

SYK has been the topic of several recent analyst reports. The Goldman Sachs Group set a $422.00 target price on shares of Stryker in a research note on Tuesday, March 4th. Barclays raised their price objective on Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Stifel Nicolaus upped their target price on Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a research note on Wednesday, January 29th. Wells Fargo & Company lifted their price target on shares of Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. Finally, Truist Financial upped their price objective on shares of Stryker from $409.00 to $413.00 and gave the stock a "hold" rating in a research report on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $423.05.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.